O	0	10	Randomized
O	11	16	trial
O	17	19	of
O	20	21	a
B-intervention	22	31	telephone
I-intervention	31	32	-
I-intervention	32	37	based
I-intervention	38	44	weight
I-intervention	45	49	loss
O	50	62	intervention
O	63	65	in
O	66	80	postmenopausal
O	81	86	women
O	87	91	with
O	92	98	breast
O	99	105	cancer
O	106	115	receiving
O	116	125	letrozole
O	125	126	:
O	127	130	the
O	131	135	LISA
O	136	141	trial
O	141	142	.

O	143	150	Obesity
O	151	153	is
O	154	164	associated
O	165	169	with
O	170	174	poor
O	175	183	outcomes
O	184	186	in
O	187	192	women
O	193	197	with
O	198	206	operable
O	207	213	breast
O	214	220	cancer
O	220	221	.

O	222	231	Lifestyle
O	232	245	interventions
O	246	247	(
O	247	250	LIs
O	250	251	)
O	252	256	that
O	257	261	help
O	262	267	women
O	268	274	reduce
O	275	280	their
O	281	287	weight
O	288	291	may
O	292	299	improve
O	300	308	outcomes
O	308	309	.

O	310	312	We
O	313	322	conducted
O	323	324	a
O	325	336	multicenter
O	337	347	randomized
O	348	353	trial
O	354	363	comparing
O	364	368	mail
O	368	369	-
O	369	374	based
O	375	383	delivery
O	384	386	of
B-control	387	394	general
I-control	395	401	health
I-control	402	413	information
I-control	414	419	alone
O	420	422	or
O	423	431	combined
O	432	436	with
O	437	438	a
O	439	441	24
O	441	442	-
O	442	447	month
O	448	460	standardized
O	460	461	,
O	462	471	telephone
O	471	472	-
O	472	477	based
O	478	480	LI
O	481	485	that
O	486	494	included
O	495	499	diet
O	500	501	(
O	501	504	500
O	505	507	to
O	508	509	1
O	509	510	,
O	510	513	000
O	514	518	kcal
O	519	522	per
O	523	526	day
O	527	534	deficit
O	534	535	)
O	536	539	and
O	540	548	physical
O	549	557	activity
O	558	559	(
O	559	562	150
O	563	565	to
O	566	569	200
O	570	577	minutes
O	578	580	of
O	581	589	moderate
O	589	590	-
O	590	599	intensity
O	600	608	physical
O	609	617	activity
O	618	621	per
O	622	626	week
O	626	627	)
O	628	633	goals
O	634	636	to
O	637	644	achieve
O	645	651	weight
O	652	656	loss
O	657	658	(
O	658	660	up
O	661	663	to
O	664	666	10
O	666	667	%
O	667	668	)
O	668	669	.

B-eligibility	670	675	Women
I-eligibility	676	685	receiving
I-eligibility	686	694	adjuvant
I-eligibility	695	704	letrozole
I-eligibility	705	708	for
I-eligibility	709	711	T1
I-eligibility	711	712	-
I-eligibility	712	715	3N0
I-eligibility	715	716	-
I-eligibility	716	719	3M0
I-eligibility	720	726	breast
I-eligibility	727	733	cancer
I-eligibility	734	738	with
I-eligibility	739	740	a
I-eligibility	741	745	body
I-eligibility	746	750	mass
I-eligibility	751	756	index
I-eligibility	757	758	(
I-eligibility	758	761	BMI
I-eligibility	761	762	)
I-eligibility	763	764	≥
I-eligibility	765	767	24
I-eligibility	768	770	kg
I-eligibility	770	771	/
I-eligibility	771	772	m
I-eligibility	772	773	(
I-eligibility	773	774	2
I-eligibility	774	775	)
O	776	780	were
O	781	789	eligible
O	789	790	.

O	791	797	Weight
O	798	801	was
O	802	810	measured
O	811	813	in
O	814	817	the
O	818	824	clinic
O	824	825	,
O	826	829	and
O	830	834	self
O	834	835	-
O	835	841	report
O	842	850	physical
O	851	859	activity
O	859	860	,
O	861	868	quality
O	868	869	-
O	869	871	of
O	871	872	-
O	872	876	life
O	877	878	(
O	878	881	QOL
O	881	882	)
O	882	883	,
O	884	887	and
O	888	892	diet
O	893	907	questionnaires
O	908	912	were
O	913	922	completed
O	922	923	.

O	924	927	The
O	928	935	primary
O	936	943	outcome
O	944	947	was
B-outcome-Measure	948	955	disease
I-outcome-Measure	955	956	-
I-outcome-Measure	956	960	free
I-outcome-Measure	961	969	survival
O	969	970	.

O	971	978	Accrual
O	979	982	was
O	983	993	terminated
O	994	996	at
B-total-participants	997	1000	338
O	1001	1003	of
O	1004	1005	2
O	1005	1006	,
O	1006	1009	150
O	1010	1017	planned
O	1018	1026	patients
O	1027	1034	because
O	1035	1037	of
O	1038	1042	loss
O	1043	1045	of
O	1046	1053	funding
O	1053	1054	.

B-outcome	1055	1059	Mean
I-outcome	1060	1066	weight
I-outcome	1067	1071	loss
O	1072	1075	was
O	1076	1089	significantly
O	1090	1091	(
O	1091	1092	P
O	1093	1094	<
O	1095	1096	.
O	1096	1099	001
O	1099	1100	)
O	1101	1108	greater
O	1109	1111	in
O	1112	1115	the
O	1116	1118	LI
O	1119	1122	arm
O	1123	1129	versus
O	1130	1133	the
O	1134	1144	comparison
O	1145	1148	arm
O	1149	1150	(
B-iv-cont-mean	1150	1151	4
I-iv-cont-mean	1151	1152	.
I-iv-cont-mean	1152	1153	3
O	1154	1155	v
B-cv-cont-mean	1156	1157	0
I-cv-cont-mean	1157	1158	.
I-cv-cont-mean	1158	1159	6
I-cv-cont-mean	1160	1162	kg
O	1163	1165	or
B-iv-cont-mean	1166	1167	5
I-iv-cont-mean	1167	1168	.
I-iv-cont-mean	1168	1169	3
I-iv-cont-mean	1169	1170	%
O	1171	1172	v
B-cv-cont-mean	1173	1174	0
I-cv-cont-mean	1174	1175	.
I-cv-cont-mean	1175	1176	7
I-cv-cont-mean	1176	1177	%
B-outcome	1178	1180	at
I-outcome	1181	1182	6
I-outcome	1183	1189	months
O	1190	1193	and
B-iv-cont-mean	1194	1195	3
I-iv-cont-mean	1195	1196	.
I-iv-cont-mean	1196	1197	1
O	1198	1199	v
B-cv-cont-mean	1200	1201	0
I-cv-cont-mean	1201	1202	.
I-cv-cont-mean	1202	1203	3
I-cv-cont-mean	1204	1206	kg
O	1207	1209	or
B-iv-cont-mean	1210	1211	3
I-iv-cont-mean	1211	1212	.
I-iv-cont-mean	1212	1213	6
I-iv-cont-mean	1213	1214	%
O	1215	1216	v
B-cv-cont-mean	1217	1218	0
I-cv-cont-mean	1218	1219	.
I-cv-cont-mean	1219	1220	4
I-cv-cont-mean	1220	1221	%
B-outcome	1222	1224	at
I-outcome	1225	1227	24
I-outcome	1228	1234	months
O	1234	1235	)
O	1236	1239	and
O	1240	1248	occurred
O	1249	1261	consistently
O	1262	1268	across
O	1269	1275	strata
O	1276	1277	(
O	1277	1280	BMI
O	1281	1283	24
O	1284	1286	to
O	1287	1288	<
O	1289	1291	30
O	1292	1293	v
O	1294	1295	≥
O	1296	1298	30
O	1299	1301	kg
O	1301	1302	/
O	1302	1303	m
O	1303	1304	(
O	1304	1305	2
O	1305	1306	)
O	1306	1307	;
O	1308	1313	prior
O	1314	1315	v
O	1316	1318	no
O	1319	1324	prior
O	1325	1333	adjuvant
O	1334	1346	chemotherapy
O	1346	1347	)
O	1347	1348	.

B-outcome	1349	1355	Weight
I-outcome	1356	1360	loss
O	1361	1364	was
O	1365	1373	greatest
O	1374	1376	in
O	1377	1382	those
O	1383	1387	with
O	1388	1394	higher
O	1395	1403	baseline
O	1404	1410	levels
O	1411	1413	of
O	1414	1422	moderate
O	1422	1423	-
O	1423	1432	intensity
O	1433	1441	physical
O	1442	1450	activity
O	1451	1453	or
O	1454	1465	improvement
O	1466	1468	in
O	1469	1472	QOL
O	1472	1473	.

B-outcome	1474	1489	Hospitalization
I-outcome	1490	1495	rates
I-outcome	1496	1499	and
I-outcome	1500	1507	medical
I-outcome	1508	1514	events
O	1515	1519	were
O	1520	1527	similar
O	1527	1528	.

O	1529	1530	A
O	1531	1540	telephone
O	1540	1541	-
O	1541	1546	based
O	1547	1549	LI
O	1550	1553	led
O	1554	1556	to
O	1557	1568	significant
O	1569	1575	weight
O	1576	1580	loss
O	1581	1585	that
O	1586	1589	was
O	1590	1595	still
O	1596	1603	evident
O	1604	1606	at
O	1607	1609	24
O	1610	1616	months
O	1616	1617	,
O	1618	1625	without
O	1626	1633	adverse
O	1634	1641	effects
O	1642	1644	on
O	1645	1648	QOL
O	1648	1649	,
O	1650	1666	hospitalizations
O	1666	1667	,
O	1668	1670	or
O	1671	1678	medical
O	1679	1685	events
O	1685	1686	.

O	1687	1697	Adequately
O	1698	1705	powered
O	1706	1716	randomized
O	1717	1723	trials
O	1724	1728	with
O	1729	1735	cancer
O	1736	1739	end
O	1740	1746	points
O	1747	1750	are
O	1751	1757	needed
O	1757	1758	.
